Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies
المؤلفون المشاركون
Humphries, Thomas J.
Rauchensteiner, Stephan
Tückmantel, Claudia
Pieper, Alexander
Maas Enriquez, Monika
Mathew, Prasad
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-08-19
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Objectives.
Prophylaxis regimens for severe hemophilia A allowing more flexible dosing while maintaining efficacy may improve adherence and decrease the cost of prophylaxis.
Here, we compared the clinical effectiveness of once- or twice-weekly versus ≥3-times-weekly prophylaxis with sucrose-formulated recombinant factor VIII (rFVIII-FS) in a “real-world” practice setting.
Methods.
Data from 3 postmarketing studies were pooled.
Patients with severe hemophilia A receiving ≥1 prophylaxis infusion/wk of rFVIII-FS for ≥80% of a prophylaxis observation period (≥5 months) were included.
Patients were categorized based on physician-assigned treatment regimens of 1-2 prophylaxis injections/wk (n=63) or ≥3 prophylaxis injections/wk (n=76).
Descriptive statistics were determined for annualized bleeding rates (ABRs).
Results.
Median (quartile 1; quartile 3) ABR for all bleeds was 2.0 (0; 4.0) in the 1-2 prophylaxis injections/wk group and 3.9 (1.5; 9.3) in the ≥3 prophylaxis injections/wk group.
Median ABRs for joint, spontaneous, and trauma-related bleeds were numerically lower with 1-2 prophylaxis injections/wk.
As an estimate of prophylaxis success, 63% (≥3 prophylaxis injections/wk) to 84% of patients (1-2 prophylaxis injections/wk) had ≤4 annualized joint bleeds.
Conclusions.
Dosing flexibility and successful prophylaxis with rFVIII-FS were demonstrated.
Very good bleeding control was achieved with both once-twice-weekly and ≥3-times-weekly prophylaxis dosing regimens.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Humphries, Thomas J.& Rauchensteiner, Stephan& Tückmantel, Claudia& Pieper, Alexander& Maas Enriquez, Monika& Mathew, Prasad. 2015. Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies. Advances in Hematology،Vol. 2015, no. 2015, pp.1-6.
https://search.emarefa.net/detail/BIM-1052440
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Humphries, Thomas J.…[et al.]. Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies. Advances in Hematology No. 2015 (2015), pp.1-6.
https://search.emarefa.net/detail/BIM-1052440
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Humphries, Thomas J.& Rauchensteiner, Stephan& Tückmantel, Claudia& Pieper, Alexander& Maas Enriquez, Monika& Mathew, Prasad. Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies. Advances in Hematology. 2015. Vol. 2015, no. 2015, pp.1-6.
https://search.emarefa.net/detail/BIM-1052440
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1052440
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر